No profile data available.
Erasca, Inc. (ERAS) is a healthcare company in the additional cancer treatment drugs industry, based in San Diego, United States, with about 103 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$124.55 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $5.61 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Erasca reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$5.61 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include ImmunityBio, Inc. (IBRX), Iovance Biotherapeutics, Inc. (IOVA), CG Oncology, Inc. (CGON), Cogent Biosciences, Inc. (COGT).